Health Care·Pharmaceuticals·$119.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.74 | N/A | -1.36% |
management commentary, guidance changes, and full analysis available with Pro.
| -1.36% |
Tone: Defensive
Management expressed concerns about market conditions affecting performance. They reiterated their focus on future product launches and pipeline strength.
Management highlighted ongoing challenges in the market.
They emphasized the importance of pipeline developments moving forward.
Bristol Myers Squibb's earnings report showed a slight miss on EPS, which contributed to a 3.11% decline in stock price. Investors may be reacting to management's cautious tone regarding market challenges and the lack of updated guidance. The focus will likely shift to the company's pipeline and future product launches as key factors for recovery.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
HALLIBURTON CO
Jul 24, 2017